Sep 2026· European journal of pharmaceutics and biopharmaceutics· pp.
115238
· 0 citations· 157 references
Medicine
TL;DR
An in-depth exploration of advanced nano-therapeutic strategies designed to multi-target angiogenic pathways, dynamically manipulate reactive oxygen species, disrupt hypoxia-driven feedback loops, reprogram the immunoinflammatory network, and restore defective cellular autophagy are provided.
Abstract
Choroidal neovascularization (CNV) is a key pathological mechanism underlying irreversible vision loss in diseases such as age-related macular degeneration (AMD). Although anti-vascular endothelial growth factor (VEGF) therapies effectively inhibit angiogenesis, they are limited by the need for frequent injections, the tendency to induce resistance, and their inability to reverse the complex pathological microenvironment driving CNV. Research indicates that the initiation and progression of CNV are cooperatively driven by the local microenvironment, particularly through the interplay of oxidative stress, hypoxia, and inflammatory networks. In recent years, the emergence of nanotechnology has provided unprecedented tools for precise modulation of this microenvironment. This review systematically delineates the mechanisms of CNV formation, with a focused analysis on the core interplay between oxidative stress, hypoxia, and inflammation. We provide an in-depth exploration of advanced nano-therapeutic strategies designed to multi-target angiogenic pathways, dynamically manipulate reactive oxygen species, disrupt hypoxia-driven feedback loops, reprogram the immunoinflammatory network, and restore defective cellular autophagy. This review aims to provide a theoretical foundation and forward-looking perspective for developing next-generation microenvironment-targeted therapies capable of intervening in CNV.
Hypoxia-inducible factor (HIF) is a key driver of ocular neovascular diseases. We systematically discuss its regulatory mechanisms and pathological roles in diabetic retinopathy (DR), retinopathy of prematurity (ROP), and neovascular age-related macular degeneration (nAMD). Upon integration of diverse upstream stimul...
Teng Liu, Yi-Fei He, Yi-Fan Liao et al.· Journal of Translational Med...· 0 citations
A noninvasive, cornea-penetrating nanodrug based on chitosan-modified lipid-polymer hybrid nanoparticles (LPNPs) for co-delivery of lutein and VEGF-silencing siRNA (Chi@Lu/si NPs) to treat AMD, which interrupts the pathological cycle driving CNV progression.
Yong Li, Fan Xiao, Zi-Wei Liu et al.· Advances in Materials· 0 citations
The results implicate the specific importance of MP cGAS/STING signaling in CNV and provide proof of concept for specific modulation of STING in MPs as a therapy for nAMD.
Le Shi, D. Cherukaraveedu, Hongkwan Cho et al.· JCI Insight· 0 citations
By overcoming key limitations of conventional antibodies, engineered nanobodies open new avenues for precise, multi-dimensional interventions in solid tumors and highlight the value of engineered Nbs as a highly programmable and transformative platform.
Yuxuan Liu, Zhao-Hai Li, Yuan-Yuan Ma et al.· Frontiers in Immunology· 0 citations
A causal link between the age-related miR-34a and neovascularization in AMD is established and miR-34a directly targets and inhibits the transcription factor KLF2, thereby upregulating the proangiogenic factors CXCR4 and CXCL12.
Jason J. Colasanti, A. Santeford, Joseph B. Lin et al.· Proceedings of the National...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.